Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
Despite mixed fan and critic reactions to the final season of "Game of Thrones," the eight-season epic took home the top prize in the drama category at the Emmy Awards on...Entertainmentread more
There are alternative financial centers and investors can turn to Singapore, Tokyo or Shanghai if Hong Kong doesn't "shape up," says the founder and chairman of Citic Capital.Asia Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
U.S. President Donald Trump's national security advisor said on Sunday that White House Asia policy adviser Matt Pottinger would become his top deputy.Politicsread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Pfizer reported quarterly revenue on Tuesday that missed Wall Street estimates, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar.
Sales of Enbrel, which Pfizer sells outside the United States and Canada, tumbled about 19.5 percent to $617 million on competition from biosimilars.
Prevnar sales declined 8.2 percent to $1.15 billion, while sales of its breast cancer treatment, Ibrance, earned $853 million, up from $514 million in the year-ago quarter.
Sales of its copycat generics and biosimilars fell 13.5 percent in the quarter to $5.23 billion, while revenue from its patent-protected drugs rose about 8 percent to $7.67 billion.
Overall, revenue fell to $12.9 billion in the second quarter from $13.15 billion, below analysts' estimates of $13.08 billion, according to Thomson Reuters I/B/E/S. However, net income attributable to the largest U.S. drugmaker rose to $3.07 billion, or 51 cents per share, from $2.05 billion, or 33 cents per share, a year earlier.
Excluding items, Pfizer earned 67 cents per share, beating the average analysts' estimate by a cent.
Looming patent expirations on Pfizer's sexual dysfunction treatment Viagra, pain drug Lyrica and falling Prevnar sales has pushed analysts to prescribe deals to resuscitate the company's growth.
"Over the next five years, we project the potential for approximately 25 to 30 approvals, of which up to 15 have the potential to be blockbusters," Chief Executive Ian Read said in a statement on Tuesday.
The drugmaker also narrowed its 2017 adjusted earnings forecast to a range of $2.54 per share to $2.60 per share. It had previously forecast a range of $2.50 per share to $2.60 per share.
The company's shares were marginally up at $33.30 before the bell on Tuesday.